)
)
Silence Therapeutics Investor Relations Material
Latest events
Study Result
Silence Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Silence Therapeutics plc
Access all reports
Silence Therapeutics plc is a biotechnology company that focuses on the discovery and development of therapeutic molecules using RNA interference (RNAi) technology. The company’s proprietary mRNAi GOLD platform is designed to develop short interfering RNA (siRNA) therapies that target and silence specific genes associated with various diseases, particularly in the liver. Silence Therapeutics is involved in developing treatments for cardiovascular conditions, hematological disorders, and rare diseases. Their leading product candidates include Zerlasiran (SLN360) for cardiovascular disease and Divesiran (SLN124) for hematological conditions. Silence Therapeutics plc is headquartered in London, United Kingdom, and its shares are listed on the NASDAQ.
Key slides for Silence Therapeutics plc
Study Result
Silence Therapeutics plc
Study Result
Silence Therapeutics plc
Latest articles
)
Mercado Libre: The Digital Backbone of Latin America
From shopping to logistics and fintech, Mercado Libre is shaping the digital transformation of Latin America.
3 Jan 2025
)
House of Pinault: The History and Business of Kering and Gucci
Kering is a luxury group under the Pinault family's leadership, managing iconic brands like Gucci, Saint Laurent, and Bottega Veneta.
19 Dec 2024
)
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
Ticker symbol
SLN
Country
🇺🇸 United States